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ABSTRACT
Regnase-1-mediated mRNA decay (RMD), in which
inflammatory mRNAs harboring specific stem–loop
structures are degraded, is a critical part of proper
immune homeostasis. Prior to initial translation,
Regnase-1 associates with target stem–loops but
does not carry out endoribonucleolytic cleavage.
Single molecule imaging revealed that UPF1 is re-
quired to first unwind the stem–loops, thus licens-
ing Regnase-1 to proceed with RNA degradation.
Following translation, Regnase-1 physically asso-
ciates with UPF1 using two distinct points of in-
teraction: The Regnase-1 RNase domain binds to
SMG1-phosphorylated residue T28 in UPF1; in addi-
tion, an intrinsically disordered segment in Regnase-
1 binds to the UPF1 RecA domain, enhancing the he-
licase activity of UPF1. The SMG1-UPF1–Regnase-
1 axis targets pioneer rounds of translation and is
critical for rapid resolution of inflammation through
restriction of the number of proteins translated by
a given mRNA. Furthermore, small-molecule inhibi-
tion of SMG1 prevents RNA unwinding in dendritic
cells, allowing post-transcriptional control of innate
immune responses.
INTRODUCTION
Control of gene expression by mRNA degradation plays
a critical role in the regulation of various biological pro-
cesses, including immune reactions, responses to cellular
stresses and maintenance of homeostasis (1,2). In mam-
mals, mRNA degradation is mediated by a set of RNases,
whose activity is tightly regulated in order to control the
abundance of specific mRNAs. There are several known
modes of regulation of RNase-mediatedmRNAdecay. One
mode affects the recruitment of RNases to the mRNAs tar-
geted for degradation. Deadenylation and subsequent de-
cay of mRNAs is controlled by recruitment of the CCR4–
NOT deadenylase complex which targets mRNAs via RNA
binding proteins (RBPs) such as tristetraprolin and Roquin
or microRNAs (3,4). Nonsense-mediated mRNA decay
(NMD) is also known to be regulated by the recruitment of
the endoribonuclease SMG6 or the CCR4–NOT complex
via SMG5-7 to aberrant mRNAs by binding with the heli-
case UPF1 (5–9). In addition to such recruitment-induced
activation of RNases, dimerization of RNases can act as
a switch to initiate mRNA digestion. For instance, the en-
doribonuclease IRE1 cleaves XBP1 pre-mRNA upon en-
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doplasmic reticulum (ER) stress by homodimerization to
induce splicing and production of XBP1 protein (10–12).
RNase L is another example of an RNase activated by its
homodimerization in response to virus infection (13,14).
Thus, control of RNA degradation by altering the confor-
mation or oligomerization state of the RNase is a well-
established mode of regulation. On the other hand, recent
studies have revealed that mRNA structures themselves in-
fluence their post-transcriptional fate, and that these struc-
tures dynamically change in response to stimuli, such as
virus infection (15,16). However, the relationship between
structural changes of mRNAs and their degradation in the
regulation of cellular responses has not been clarified.
Regnase-1 (also known as Zc3h12a and Mcpip1) is an
endoribonuclease essential for the maintenance of immune
and iron homeostasis (17,18). Regnase-1 suppresses in-
flammation by promoting decay of immune-related mR-
NAs, including Interleukin 6 (IL6), IL12B, PTGS2 and
NFKBIZ––but not NFKBIA––in innate immune cells fol-
lowing stimulation with Toll-like receptor (TLR) ligands
such as lipopolysaccharide (LPS) and IL-1 (17,19,20).
Macrophages from Regnase-1-deficient mice express the
target mRNAs abundantly, and produce elevated amounts
of proinflammatory cytokines, which contributes to the
development of severe autoimmunity. For these reasons
Regnase-1 activity must be tightly regulated at multi-
ple levels. Crosslinking and immunoprecipitation sequenc-
ing (CLIP-Seq) analysis revealed that Regnase-1 recog-
nizes mRNAs harboring stem–loop structures with a
pyrimidine–purine–pyrimidine (Py–Pu–Py) loop sequence
present in the 3′ untranslated regions (3′ UTRs) of tar-
get mRNAs as cis-elements (21). The stem–loop struc-
ture is recognized not only by Regnase-1 but also Roquin,
an RNA-binding protein critical for the maintenance of
immune homeostasis (20,22,23). However, Regnase-1 and
Roquin function by spatiotemporally distinct mechanisms.
Regnase-1 and Roquin tend to control mRNAs at the
early and late phase of inflammation, respectively. Whereas
Roquin destabilizes translationally inactive mRNAs by re-
cruiting the CCR4–NOT complex in processing-bodies
(PBs) and stress granules (SGs), Regnase-1 localizes to the
ER and ribosomes, destabilizes translationally active mR-
NAs and requires the RNA helicase, UPF1, which is also
essential for NMD (21). In NMD, phosphorylated UPF1 is
recruited to nonsense mRNAs and interacts with SMG6 or
the SMG5-7 complex (7). The helicase/ATPase activity of
UPF1 is required for disassembly of messenger ribonucleo-
proteins (mRNPs) undergoing NMD (24), and also for its
preferential release fromnon-targetmRNAs (25). Although
it has been demonstrated that Regnase-1-mediated decay
(RMD) depends on UPF1 in a translation-dependent man-
ner, the role of this interaction in the regulation of Regnase-
1 activity has not yet been elucidated.
In this study, we found that structural changes in the
stem–loop RNA mediated by UPF1 function as the struc-
tural switch for execution of RMD. The UPF1–Regnase-
1 interaction is induced subsequent to a pioneer round of
translation, whereas Regnase-1 recruitment to target mR-
NAs occurs irrespective of translation termination. Muta-
tional analysis revealed that the phosphorylation of UPF1
at T28 by the kinase SMG1 following translation is required
for stable interaction between UPF1 and Regnase-1. Fur-
thermore, inhibition of SMG1 kinase activity with a specific
inhibitor induces DC maturation and potentiates T cell-
stimulatory activity. Collectively, this study reveals a hereto-
fore undescribed mechanism of mRNA decay triggered not
by conformational changes in the RNase but in the RNA,
and thus represents an additional level of RNase-mediated
control of inflammatory responses.
MATERIALS AND METHODS
Mice
Mice deficient in Regnase-1 have been described (17). San-
roque mice were kindly provided by Dr Masakazu Hattori
(KyotoUniversity). C57BL/6J and BALB/c mice were pur-
chased from CREA Japan. All animal experiments were
done with the approval of the Animal Research Commit-
tee of the Institute for Frontier Life and Medical Sciences
and Graduate School of Medicine, Kyoto University.
Cell culture
HeLa cells and HEK293T cells were purchased from
ATCC and maintained in DMEM (Nacalai Tesque) sup-
plemented with 10% (vol/vol) FBS (Gibco), 100 U/ml of
penicillin (Nacalai Tesque), 100 g/ml of streptomycin
(Nacalai Tesque) and 50 M -mercaptoethanol (Nacalai
Tesque). Tet-off HEK293T cells were purchased fromClon-
tech and maintained in -MEM (Nacalai Tesque) supple-
mented with 10% (vol/vol) FBS (Clontech), 50 M -
mercaptoethanol and 100 g/ml G418 (Nacalai Tesque).
Regnase-1–/– HeLa cells were generated by CRISPR-
Cas9 gene editing as previously reported method (26).
Briefly, to delete target genes, SpCas9-expressingHeLa cells
were lentivirally transduced with a plasmid carrying re-
spective sgRNA (target sequence for human Regnase-1,
5′-TGAGACCAGTGGTCATCGAT-3′) and selected with
puromycin (1 g/ml) for 7 days. Selected cells were pooled
and validated for gene deletion by immunoblot analysis.
Primary MEFs were prepared from wild-type, Regnase-
1–/–, Roquinsan/san mouse embryos at embryonic day
13.5 and maintained in DMEM supplemented with 10%
(vol/vol) FBS (Gibco) and 50 M -mercaptoethanol.
Peritoneal macrophages were prepared from mice 3 d af-
ter intraperitoneal injection of 4% (vol/vol) thioglycollate
medium (2ml) (Sigma) and weremaintained in RPMI-1640
medium (Nacalai Tesque) supplemented with 10% (vol/vol)
FBS (Gibco) and 50 M -mercaptoethanol.
For preparation of bone marrow–derived macrophages
(BMMs), bone marrow cells were isolated from wild-
type, Regnase-1–/– or Roquinsan/san mice and cultured in
macrophage growth medium (RPMI-1640 medium sup-
plemented with 10% (vol/vol) FBS (Gibco), 50 M -
mercaptoethanol, 100 U/ml of penicillin, 100 g/ml
of streptomycin and 20 ng/ml of macrophage colony-
stimulating factor (BioLegend)). After 5 days, cells were
washed once and cultivated for 2 days with macrophage
growth medium, then cells were collected for further analy-
sis.
For preparation of bone marrow–derived dendritic cells
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type or Regnase-1–/– mice and cultured in dendritic cell
growth medium (RPMI-1640 medium supplemented with
10% (vol/vol) FBS, 50 M -mercaptoethanol, 100 U/ml
of penicillin, 100g/ml of streptomycin, 250 ng/ml ampho-
tericin B and 10 ng/ml of murine granulocyte-macrophage
colony-stimulating factor (PeproTech). Every 2 days, non-
adherent cells were discarded and remaining cells were fed
with fresh dendritic cell growth medium. At day 6, loosely
adherent cells were harvested and used for indicated assays.
METHOD DETAILS
DNA and siRNA transfection
Cells were transfected with plasmid DNAs through the use
of Lipofectamine 2000 or Lipofectamine LTX (Thermo
Fisher Scientific) according to the manufacturer’s recom-
mendations.
For siRNA-mediated knockdown, cells were trans-
fected through the use of Lipofectamine RNAiMAX
(Thermo Fisher Scientific) or MISSION siRNA Trans-
fection Reagent (Sigma). The siRNAs used in this study
were synthesized by Thermo Fisher Scientific and the





Plasmid construction and reagents
The cDNAs ofmouseRegnase-1 (Zc3h12a), Regnase-1mu-
tants and mouse Il6 have been described (17). The cDNAs
of mouse Roquin-1 (Rc3h1) was kindly provided by Georg
Stoecklin (German Cancer Research Center). The cDNAs
of Regnase-1, Roquin and human UPF1 were ligated to the
vector pFlag-CMV2 (SIGMA), pcDNA3.1(+) (Invitrogen),
pEGFP-C1 (Clontech), pmCherry-C1 (Clontech) and pSR
(7) for mammalian expression. The cDNA of Il6 CDS-3′
UTR was inserted in pTREtight vector (Clontech). The 3′
UTR cDNAs of a set of genes were inserted in the pGL3-
promoter (Promega).
Mammalian expression vectors for wild-type hu-
man UPF1 and its mutants [pSR-HA-hUPF1-WT
(amino acids 6–1118), pSR-HA-hUPF1-WTR (amino
acids 6–1118), pSR-HA-hUPF1-NT (amino acids
64–1118), pSR-HA-hUPF1-CT (amino acids 6–
1027), pSR-HA-hUPF1-NCT (amino acids 64–
1027), pSR-HA-hUPF1-T28A, pSR-HA-hUPF1–4SA
(SSSS1073/1078/1096/1116AAAA), pSR-HA-hUPF1-
T28E] were previously described (7,21). siRNA resistance
mutants of wild type human SMG1 and its mutants [pSR-
Flag-hSMG1-WTR and pSR-Flag-hSMG1-D2331AR]
were generated by standard methods. pSR-HA-hUPF1-
CH (amino acids 295–914), pSR-HA-hUPF1-(428–
964), pSR-HA-hUPF1-(6–429), pSR-HA-hRIG-I-WT
(amino acids 2–925), pEFh-SBP-GFP-hUPF1-(295–914),
pEFh-SBP-GFP-hUPF1-(416–914) and pEFh-SBP-
GFP-hUPF1-(610–914) were made by standard cloning
procedures. The cDNAs of human UPF1 (6–429) were
ligated to the vector pEGFP-C1 (Clontech) for mammalian
expression. The targeted mutations into Regnase-1 and
UPF1 genes were introduced by QuikChange Lightning
Site-Directed Mutagenesis Kit (Agilent). pCMV-Myc-
hUPF1-G495R/G497E was kindly provided by Lynne E.
Maquat (University of Rochester).
LPS derived from Salmonella minnesota, Pam3CSK4,
R848, CpG oligonucleotide ODN1668 and puromycin
were purchased from Invivogen; Recombinant cytokines
were purchased from R&D Systems; Anisomycin, 5,6-
dichloro-1-beta-D-ribofuranosylbenzimidazole (DRB),
Emetine and actinomycin D were purchased from Sigma;
-Amanitin was purchased from Wako; SMG1 inhibitor
(referred to as ‘Compound 11J’ in (27)) was purchased
from TLC Pharmaceutical Standards; Compund 11J
(SMG1 inhibitor), KU-60019 (ATM inhibitor), VE-821
(ATR inhibitor) and NU7441 (DNA-PK inhibitor) were
purchased from Selleckchem.
Immunoblot analysis
Whole-cell extracts were prepared in lysis buffer (1%
(vol/vol) Nonidet P-40, 0.1% (wt/vol) SDS, 1% (wt/vol)
sodium deoxycholate, 150 mM NaCl, 20 mM Tris–HCl,
pH 8.0, 10 mM EDTA and Complete Mini Protease In-
hibitor Cocktail without EDTA (Roche)) and suspended in
SDS sample buffer (50 mM Tris–HCl, pH 6.8, 2% (wt/vol)
SDS, 5% (vol/vol) -mercaptoethanol, 10% (vol/vol) glyc-
erol and bromophenol blue). Proteins were boiled for 5
min at 95◦C, resolved on polyacrylamide gels (e-PAGEL;
ATTO) and transferred onto 0.2 m pore size Immun-
Blot PVDF membranes (Bio-Rad). Membranes were incu-
bated with indicated primary antibodies and HRP-coupled
secondary antibodies (NA9310 and NA9340; GE Health-
care). The following primary antibodies were used for im-
munoblot analysis: antibody to Flag (F3165 and F7425;
Sigma), HA (H6908 and H3663; Sigma), GFP (ab1218 and
ab290; Abcam), mCherry (ab125096 and ab183628; Ab-
cam), SBP (ab119491; Abcam), CBP80 (A301; Bethyl Lab-
oratories), eIF4E (#9742; CST), PABPC (#4992; CST),
SMG1 (A300-393A; Bethyl Laboratories), IB (sc-371;
Santa Cruz), Roquin-1 (A300-514A; Bethyl Laboratories),
Roquin-2 (ab99090; Abcam), Ptgs2 (ab15191; Abcam)
and -actin (sc-1615; Santa Cruz). Rabbit IB-z (NFK-
BIZ) polyclonal antibody was kindly provided by Tat-
sushi Muta (Tohoku University). Rabbit Regnase-1 anti-
body was described (19). Rabbit anti-UPF1 affinity anti-
body, rabbit anti-P-T28-UPF1 antibody and mouse anti-P-
S1078/S1096-UPF1 monoclonal antibody (cone 8E6) were
previously described (7,28,29). The anti-P-S1078/S1096-
UPF1 antibody recognizes both phosphorylated S1078 and
S1096 residues (7). Membranes were treated with Luminata
ForteWestern HRP substrate (Millipore) and luminescence
was detectedwith a luminescent image analyzer (Amersham
Imager 600; GE Healthcare).
Northern blotting
Total RNAs were isolated using ISOGEN II (Wako) or Tri-
zol (Invitrogen), electrophorated, blotted to Hybond-N+
(GE healthcare) and hybridized with the probes for Il6 and
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exposed to an imaging plate and analyzed by BAS-5000
imaging analyzer (Fuji Film). Primers used for producing
probes were shown in Supplementary Table S3.
Quantitative PCR analysis
Total RNAs were isolated using ISOGEN II (Wako) or
Trizol (Invitrogen) and reverse-transcribed using Rever-
Tra Ace (Toyobo) according to the manufacturer’s instruc-
tions. For quantitative PCR, cDNA fragments were ampli-
fied through the use of universal SYBR Select Master Mix
(Thermo Fisher Scientific). Fluorescence was detected with
a StepOne Real-Time PCR System (Applied Biosystems).
Primers used for qPCR were shown in Supplementary Ta-
ble S3. The abundance of mRNA of each expressed gene
was normalized to that of -Actin.
Protein IP
HeLa cells transfected with the indicated siRNA and ex-
pression plasmids were lysed in lysis buffer (0.1% (vol/vol)
Nonidet P-40, 150 mM NaCl, 10 mM Tris–HCl, pH 8.0
and Complete Mini Protease Inhibitor Cocktail without
EDTA (Roche)). The indicated antibodies, anti-Flag anti-
body (F3165; Sigma) or anti-GFP antibody (ab1218; Ab-
cam), bound to protein G magnetic beads (Invitrogen) was
incubated for 3 h at 4◦C with lysates. Beads were washed
three times with lysis buffer and suspended in SDS sam-
ple buffer (50 mM Tris–HCl, pH 6.8, 2% (wt/vol) SDS, 5%
(vol/vol) -mercaptoethanol, 10% (vol/vol) glycerol and
bromophenol blue). Samples were boiled for 5 min at 95◦C
and analyzed by western blot with the indicated antibodies.
RNA IP
HeLa cells and Tet-off 293T cells transfected with the in-
dicated siRNA and expression plasmids were lysed in RNA
IP lysis buffer (0.1% (vol/vol) Nonidet P-40, 150mMNaCl,
20 mM Tris–HCl, pH 7.5, Complete Mini Protease In-
hibitor Cocktail without EDTA (Roche) and 0.2 U/ml
RNasin (Promega)). The indicated antibodies, anti-Flag an-
tibody (F3165; Sigma), normal rabbit IgG (MLB), anti-
CBP80 mouse monoclonal clone 38A1 antibody or anti-
eIF4E antibody (RN001P;MLB), bound to proteinGmag-
netic beads (Invitrogen) was incubated for 3 h at 4◦C with
lysates and beads were washed three times with RNA IP
lysis buffer. Anti-CBP80 antibody was kindly provided by
MutsuhitoOhno inKyotoUniversity and details of the gen-
eration of anti-CBP80 antibody is described (30). RNAs
were eluted from the beads using Trizol reagent (Invitrogen)
according to the manufacturer’s instructions and analyzed
by RT-qPCR. Proteins were eluted from the beads using
SDS sample buffer (50 mM Tris–HCl, pH 6.8, 2% (wt/vol)
SDS, 5% (vol/vol) -mercaptoethanol, 10% (vol/vol) glyc-
erol and bromophenol blue) and analyzed by Western blot
with the indicated antibodies.
RNA immunoprecipitations (RIP)-sequencing analysis
RNA immunoprecipitationwas performedwithRegnase-1-
WT and -KOHeLa cells in biological duplicate as described
above. The quality of RNA was analyzed by the Bioana-
lyzer Nano 6000 chip (Agilent Technologies). RNA library
was prepared using Sureselect Strand mRNA kit (Agilent
Technologies) and sequenced on a HiSeq 3000 system (Il-
lumina) according to the manufacturer’s instructions. Ap-
proximately 52–70 million RNA reads were obtained. The
resulting set of trimmed reads were then mapped against
the human genome (hg19; NCBI). Analysis of enrichment
of mapped reads in the Regnase-1 RIP KO samples vs WT
samples for CBP80, eIF4E and total input RNA were per-
formed using the R package, edgeR (31), as follows. The
count of mapped reads to each gene was used as input for
the method. The coverage of each sample and the disper-
sions were estimated from the read count data using the
functions provided in the package. Finally, differential tag
counts for each gene between the RIP KO and WT sam-
ples for CBP80, eIF4E and total input RNA were esti-
mated based on a negative binomial distribution respec-
tively. Genes with an adjusted p value for enrichment in the
RIP samples <1e–2 were regarded as candidate Regnase-1
targets.
Analysis of overlap with between Regnase-1 targets and en-
richments in CBP80/eIF4E RIP-seq
The overlap between the targets of Regnase-1 and those
from the Regnase-1 RIP CBP80, eIF4E and total input
RNA experiments were evaluated using three measures.
First, we employed the Gene Set Enrichment Analysis
(GSEA)methodology, as described (32). In this case, we ob-
tained a set of genes S, defined from a previous publication
(21). On the other hand, a ranked list L was obtained by
sorting the genome-wide set of genes by their enrichment in
the RIP-seq CBP80, eIF4E and total input RNA samples
respectively. The distribution of S in L was evaluated by cal-
culating an Enrichment Score (ES) and the estimation of a
significance level for ES by 1,000 random permutations, as
described (32). The P value of enrichment of S in the top of
L was estimated as the fraction of permuted samples.
mRNA Decay assay
Doxycycline (1g/ml) (Sigma) or actinomycinD (1g/ml)
was added to the medium for the indicated time intervals
before harvesting Tet-off HEK293T cells or HeLa cells,
respectively. Total RNA was isolated using ISOGEN II
(Wako) or Trizol (Invitrogen). mRNA levels were deter-
mined either by northern blot or by RT-qPCR analysis.
Luciferase assay
HeLa cells and HEK293T cells were transfected with lu-
ciferase reporter plasmid pGL3 containing the 3′ UTR
of indicated genes, together with expression plasmid for
Regnase-1 or empty (control) plasmid. After 24 h of cultiva-
tion, cells were lysed, and luciferase activity in lysates was
determined with the Dual-Luciferase Reporter Assay sys-
tem (Promega). The gene encoding Renilla luciferase was
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Recombinant proteins
Recombinant Regnase-1 protein has been previously de-
scribed (17,21). For preparation of HA-UPF1 protein,
HeLa cells were transfected with expression vectors forHA-
UPF1 and lysed in lysis buffer (0.1% (vol/vol) Nonidet P-
40, 150 mMNaCl, 10 mM Tris–HCl, pH 8.0 and Complete
Mini Protease Inhibitor Cocktail without EDTA (Roche)).
The HA-UPF1 protein was purified by HA tagged protein
purification kit (MBL) according to themanufacturer’s pro-
tocol.
In vitro RNA cleavage assay
In vitro RNA cleavage assay has been previously described
(17,21). Briefly, 5′-[32P]-labeled RNAs (0.25 pmol) were
mixedwith recombinant Regnase-1 protein (0.75 pmol) (21)
and HA-UPF1 protein in a cleavage buffer (25mMHEPES
(pH 7.5), 50mM potassium acetate, 5mM DTT, 5mM
magnesium acetate, 2 mM ATP and 0.2 U/ml RNasin
(Promega)) at 37◦C. The cleaved RNAs were analyzed by
denaturing TBE–urea gel (Invitrogen) and autoradiogra-
phy. For two-step reaction for UPF1 and Regnase-1, 5′-
[32P]-labeled RNAs were incubated with HA-UPF1 at 37◦C
for 10 min, immediately cooled at 4◦C and then imme-
diately (within 5 min) started the reaction with Regnase-
1. The UPF1-mediated change in the RNA structure was
kept just before the start of incubation with Regnase-1. The
RNAs were analyzed by denaturing TBE–urea gel and na-
tive PAGE electrophoresis.
ATPase assay
The proteins were incubated in a reaction buffer (25mM
HEPES (pH7.5), 50mM potassium acetate, 5mM DTT,
5mM magnesium acetate, 2 mM ATP, 0.01 pmol/l RNA
and 0.2U/mlRNasin) at 37◦Cand phosphates fromUPF1-
mediated hydrolysis of ATP were measured by BIOMOL
GREEN reagent (Enzo Life Sciences Inc).
Unwinding assay
5′-[32P]-labeled RNAs (0.25 pmol) were incubated with
Regnase-1 (0.75 pmol) andHA-UPF1 in the cleavage buffer
without Mg2+, purified by QIAquick Nucleotide Removal
Kit (QIAGEN, 28304) at 4◦C. The RNAs were analyzed by
native PAGE electrophoresis and autoradiography.
GST pull-down assay
GST-Regnase-1 was incubated with HA-UPF1 in a reac-
tion buffer [0.1% NP-40, 10 mM Tris–HCl (pH8.0), 150
mM NaCl, 5 mM Mg(OAc)2, 5 mM ZnCl2, 1 mM DTT,
10% glycerol] for 1 h at r.t., immunoprecipitated with Glu-
tathione Sepharose for 1 h at 4◦C. The sepharose beads were
washed three times with the reaction buffer and the complex
was analyzed by western blot.
High-speed atomic force microscopy (AFM) observation
DNA frame formation. DNA frame used in the experiment
was designed and prepared as previously reported method
(33,34). The DNA frame was assembled in a 20 l solu-
tion containing 10 nM of M13mp18 single-stranded DNA
(Tilibit nanosystems, Munich, Germany), 40 nM of staple
strands (226 strands), 20 mM Tris–HCl (pH 7.6), 1 mM
EDTA, and 10mMMgCl2. Themixture was annealed from
85 to 15◦C at a rate of −1.0◦C/min.
Preparation of RNA strands. RNA strands containing spe-
cific stem/hairpin or non-specific sequence were prepared
using in vitro transcription. The DNA template containing
T7 promotor and target sequence was prepared by PCR
amplification. Transcription was performed at 42◦C for 2
h in a 40 l solution containing 0.1 MDNA template, T7
RNA polymerase (100 units, Takara, Kyoto, Japan), and 1
mMNTP. The reaction mixture were purified using Qiagen
RNA purification kit.
Incorporation of RNA strands into the DNA frame. For
incorporation of the RNA strands, two DNA connector
strands were used to hybridize with RNA strand and fix
to the DNA frame. After annealing, the pre-assembled
DNA/RNAhetero duplexwere incorporated into theDNA
frame by annealing the mixture from 40 to 15◦C at a rate
of −1.0◦C/min using a thermal cycler. The sample was pu-
rified by gel-filtration (GE sephacryl-400, GE Healthcare
Japan, Tokyo, Japan).
Reaction with Regnase-1 and UPF1 in the DNA frame. For
AFM observation, DNA frame (3.8 nM) with substrate
RNA was incubated with Regnase-1 (125 nM) and UPF1
in a reaction buffer (25mMHEPES (pH7.5), 50mMpotas-
sium acetate, 5mM DTT, 5mM magnesium acetate, 2 mM
ATP) at 30◦C for 10 min. After the incubation, 2 l of
the three times diluted sample was deposited onto a freshly
cleaved mica disc. After 5 min incubation, the absorbed
sample was washed with 2 l of the imaging buffer six times
and imaged in the same buffer.
AFM imaging. Imaging was performed using a high-speed
AFM (Nano Live Vision, RIBM, Tsukuba, Japan). The
sample was imaged in the imaging buffer solution at ambi-
ent temperature using an ultra-short cantilever (USC-F1.2-
k0.15, Nanoworld, Switzerland). These cantilevers have a
spring constant of 0.15 N/m with a resonant frequency of
1200 kHz in water. The 320 × 240 pixel images were ob-
tained at a scan rate of 0.2 frames per second (fps).
Mathematical model
We constructed a mathematical model based on the as-
sumption that the relationship between mRNA and pro-
tein levels of PTGS2 in experiment can be approximated
by mass action and Hill equations (Figure 6G and H). The
equations of the mathematical model are described as fol-
lows:
d[CmRNA]
dt = k1 · signal(t) − k2[CmRNA]
−k3[CmRNA] − k4[Reg1][CmRNA]
d[EmRNA]
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d[Protein]




where CmRNA is the amount of CBP80-bound mRNA,
EmRNA is the amount of eIF4E-bound mRNA, Protein is
the amount of a protein,Regnase-1 is theRegnase-1 activity,
Roq is theRoquin activity, signal(t) is stimulus-induced gene
expression, ki (i= 1,. . . ,10) is reaction rates, km is half max-
imal effective concentration of translation from EmRNA,
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Regnase-1 and Roq are employed as interpolation of
experimental data using the function pchip of MATLAB
R2014a (MathWorks, Natick MA) (Supplementary Figure
S6B). First, we fit the parameter values of k1,. . . , k7 against
mRNAs for PTGS2 andNFKBIZ in experiments using dif-
ferent parameter values in signal(t). Then, the other param-
eters were fitted against proteins of PTGS2 and NFKBIZ
in experiments. The parameter values are listed in Tables
S1 and S2. Simulations were performed using the function
ode15s of MATLAB R2014a (MathWorks, Natick MA).
Sensitivity analysis
The single parameter sensitivity of each reaction is defined
by




where q is the target function, p = (p1,p2,. . . ,pn) is the ki-
netic parameter vector, and pi is the ith kinetic parameter.
We used integrals of time courses of eIF4E-mRNAand pro-
tein as target function in Supplementary Figure S6G and
H, respectively, and the sensitivity for 1% change of each
kinetic parameter.
Structure modelling
The structural model of phosphothreonine (P-Thr) docked
to the Regnase-1 RNase domain (134–296) via K257R258
was constructed using Autodock Vina version 1.1.2 forMa-
cOSX (36). The P-Thr coordinates were downloaded from
SwissSideChain (37) and the Regnase-1 coordinates were
taken from Protein Data Bank entry 3V33. The docking
was performed within a sphere of radius 10A˚ centered at
residue Arg 254 using default parameters and the lowest-
energy pose was retained.
ELISA for culture supernatants
BMDCs from C57BL/6J mice were treated with or with-
out 0.3 M SMG1 inhibitor and stimulated with 10 ng/ml
Pam3CSK4 (Invivogen), 100 ng/ml LPS (Invivogen), 100
nM R848 (Invivogen) or 100 nM ODN1668 (Invivogen)
for 24 h and cytokine levels in culture supernatants were
measured by cytokine-specific ELISA kits (affymetrix eBio-
science) following manufacturer’s protocols.
Flow cytometry
BMDCs were cultured with 1 ng/ml Pam3CSK4 (Invivo-
gen) and/or 0.3 MSMG1 inhibitor for 48 hr, stained with
indicated antibody for 30min at 4 ◦C and washed twice
with FACS buffer (0.5% (wt/vol) BSA and 2 mM EDTA in
PBS). The following antibodies were used for flow cytomet-
ric analysis: anti-CD11c (117308; BioLegend), anti-CD40
(124612; BioLegend) and anti-CD80 (104713; BioLegend).
Data were acquired by FACSVerse and LSRFortessa X-20
(BD Biosciences), and analyzed using FlowJo.
Mixed lymphocyte reaction
BMDCs fromC57BL/6Jmice (CREAJapan)were cultured
with 1 ng/mlPam3CSK4 (Invivogen) and/or 0.3MSMG1
inhibitor for 48 h, washed, irradiated at a dose of 30 Gy
and plated at 3-fold serial dilutions in 96-well round-bottom
plates. These stimulator BMDCs were cocultured for 3
days with 5 × 104 cells/well of splenic CD4+ T cells from
BALB/c mice (CREA Japan). CD4+ T cells were isolated
by using autoMACS with CD4(L3T4) microbeads (Mil-
tenyi Biotec). [3H]Thymidine was added for the last 16 h
and [3H]thymidine incorporation was measured using a mi-
croplate scintillation counter, TopCount NXT (Packard).
Quantification and statistical analysis
Unless otherwise indicated, data are presented as means ±
SD (n = 3). Statistical significance was calculated with a
Student’s t test. Significance was accepted at the level of P
< 0.05 (*), P < 0.01 (**), or P < 0.001 (***). Western blot
images were quantitated by Amersham Imager 600 (GE
Healthcare) with ImageQuant TL software (GE Health-
care). Autoradiographic images were quantitated by BAS-
5000 imaging analyzer (Fuji Film) with Multi Gauge soft-
ware (Fuji Film).
RESULTS
Regnase-1 interacts with, but does not degrade, untranslated
stem–loop mRNAs
To determine if Regnase-1 is recruited to its target
mRNA following translation, we performed an RNA-
immunoprecipitation (RIP) assay in HeLa cells transiently-
expressing Flag-Regnase-1. As shown in Figure 1A and
Supplementary Figure S1A, Regnase-1 interacts with its
target mRNAs, including IL6, PTGS2 and NFKBIZ,
but not the non-target NFKBIA. Inhibition of transla-
tion by treatment with anisomycin did not decrease the
RNA-Regnase-1 interaction, although anisomycin treat-
ment completely blocked RMD (21). Noteworthy, we have
previously shown that the interaction between Regnase-1
and target mRNA is UPF1-independent (21). These results
indicate that translation and UPF1 are not necessary for
the recruitment of Regnase-1 to its target stem–loop RNAs,
and suggests that RMD requires an additional switch dur-
ing translation in cells.
To investigate the switchingmechanismofRMD,we tried
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Figure 1. Regnase-1 does not degrade stem–loop RNA on target mRNAs. (A) mRNAs associated with Regnase-1 in HeLa cells transfected with indicated
expression plasmids, stimulated with IL-1 (10 ng/ml) and treated with anisomycin (10 g/ml) for 2 h were analyzed by RIP-qPCR. (B) The stem–loop
RNAs are not cleaved by Regnase-1 in vitro cleavage assay. Indicated 5′-32P-labeled RNAs were incubated with Regnase-1 for indicated time, and analyzed
by TBE–urea gel electrophoresis. (C) Illustration of DNA origami frame with Il6 3′ UTR-(87–102) stem–loop RNA. (D) AFM images of complex of DNA
frame with Il6 RNAs. (E) The volume of Regnase-1 particles was calculated from AFM imaging by scanning probe image processor (SPIP) software (N
= 24). Two distinct populations were observed and peaks in the volume distribution are apparent at ∼250 and ∼400 nm3. (F and G) Time-lapse AFM
images of complex of DNA frame with indicated Il6 stem–loop RNAs and Regnase-1. Time 0 s is an arbitrary time during the AFM scanning. Scanning
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this end, we incubated recombinant Regnase-1 with tar-
get stem–loop RNAs corresponding to Il6 3′ UTR-(87–
102) and Nfkbiz 3′ UTR-(103–119) (21). Unexpectedly, we
found that Il6 and Nfkbiz stem–loops were resistant to
degradation by Regnase-1 at least 30 min of incubation in
the cleavage buffer (Figure 1B and Supplementary Figure
S1B). Since Regnase-1 prefers to cleave unstructured single-
strandedRNA (ssRNA) in a sequence-independentmanner
in vitro (38), we hypothesized that the partially unwound
stem–loop RNA can function as the substrate of Regnase-
1. We thus performed in vitro cleavage assay with RNAs
predicted to form only 2 nt stem–loop (stem mutant for
Il6 and Nfkbiz 3′ UTRs) and found that Regnase-1 cleaved
the stem mutants (Figure 1B and Supplementary Figure
S1A). ARegnase-1 mutant lacking RNase activity (D141N,
DN) did not cleave the stem mutants (Supplementary Fig-
ure S1B). To directly visualize RMD at a single-molecule
level, we performed time-lapse high-speed atomic force mi-
croscopy (AFM) analysis (33,34). AFMwith DNA origami
technology allows precise placement of target molecules in
the designed nanostructures and enables molecules to be
detected at the single-molecule level and we applied the
AFMwith DNA origami technology to visualizing and an-
alyzing the RMD. Here, to examine the reaction, the Il6
stem–loop and stem mutant RNAs were hybridized within
a DNA origami frame (Figure 1C) and the RNA substrate
attachment was observed by AFM (Figure 1D). We then
incubated monomeric Regnase-1 (Figure 1E and Supple-
mentary Figure S1C) with an Il6 stem–loop RNA-DNA
frame and found that Il6 stem–loop RNA was not cleaved
by Regnase-1 under the same condition as the in vitro cleav-
age assay, although Regnase-1 moved along the RNA and
bound the Il6 stem–loop RNA (Figure 1F and Supplemen-
tary Movie S1). In contrast, Regnase-1 rapidly degraded
Il6 stem mutant and dissociated from it (Figure 1G and
Supplementary Movie S2). These results indicate that the
stem–loop structure halts RMD, though it is necessary for
Regnase-1 recognition.
Stem-loop unwinding by UPF1 licenses RNA cleavage by
Regnase-1
Since interaction between Regnase-1 and UPF1 during
translation is essential for RMD (21), we hypothesized that
the presence of UPF1 could be a key to recapitulating
RMD in vitro. Therefore, we prepared wild-type (WT) and
ATPase/helicase inactive mutant (D648A/E649A; DEAA)
of UPF1 (Supplementary Figure S1D) (24). We next per-
formed time-lapse high-speed AFM imaging in the pres-
ence of UPF1 and observed that a single molecule of UPF1
stably bound to the Il6 stem–loop and did not cleave the
RNA (Figure 2A). Interestingly, co-incubation of Regnase-
1 and UPF1 on the Il6 stem–loop-DNA frame led to rapid
cleavage of the Il6 stem–loop, and subsequent dissociation
of Regnase-1 and UPF1 from the RNA (Figure 2B and
Supplementary Movie S3). In contrast, Regnase-1 failed to
cleave Il6 stem–loop RNA in the presence of the DEAA
mutant UPF1 (Figure 2C and Supplementary Movie S4).
Furthermore, an in vitro RNA cleavage assay revealed that
Regnase-1 degraded Il6 and Nfkbiz stem–loops in the pres-
ence of WT, but not DEAA mutant UPF1 (Figure 2D and
Supplementary Figure S1E), indicating that the UPF1 heli-
case activity is essential for the cleavage of stem–loopRNAs
by Regnase-1. To investigate whether cleavage by Regnase-
1 requires UPF1-mediated structural changes in the RNA,
we initially pretreated Il6 stem–loop RNA with UPF1 and
checked for RNA structural changes (Figure 2E). We found
that treatment with UPF1 indeed induced RNA unwind-
ing (Figure 2F), and that the unwound RNA was cleaved
by Regnase-1 even in the absence of UPF1 (Figure 2G
and Supplementary Figure S1F). These results indicate that
Regnase-1 is competent to act as a nuclease even without
UPF1, and that the unwinding of the stem–loop by UPF1
licensesRNAcleavage byRegnase-1 (Figure 2H). TheRNA
structural change induced by UPF1 thus serves as a switch
to execute RMD.
Regnase-1 binding blocks UPF1 intramolecular auto-
inhibition
We next addressed the question of how the RNA structural
change is regulated by UPF1 in response to translation ter-
mination. Interestingly, the presence of Regnase-1 signifi-
cantly enhanced the ATPase activity of UPF1 in vitro (Fig-
ure 3A). UPF1 DEAA mutant showed no ATPase activity
in the presence of Regnase-1 (Supplementary Figure S1G).
Moreover, measurement the helicase activity of UPF1 by
native gel analysis of Il6 stem–loop RNA revealed that ad-
dition of Regnase-1 accelerated the unwinding of RNA by
UPF1 (Figure 3B). These results indicate that the interac-
tion between UPF1 and Regnase-1 promotes the ATPase
and helicase activities of UPF1.
We next investigated the mechanism of Regnase-1-
mediated control of UPF1 by identifying regions responsi-
ble for their interaction. UPF1 harbors an N-terminal reg-
ulatory region followed by a cysteine-histidine-rich domain
(CH-domain), a RecA helicase domain and a C-terminal
regulatory region (Figure 3C). The CH domain functions
to suppresses the ATPase/helicase activity via intramolec-
ular interactions with the RecA domain (39). Consistent
with the previous study, the ATPase activity of a trun-
cated mutant of UPF1 (CH, aa 295–914) was higher than
that of WT UPF1 (Supplementary Figure S1D). Regnase-
1 had no effect on ATPase activity of UPF1-CH mutant
(Figure 3A). Co-immunoprecipitation using UPF1 lack-
ing the N-terminal (N), C-terminal (C) or both the N-
and C-terminal regions (NCT) revealed that full-length
and NCT, but not N, UPF1 associated with Regnase-
1 (Figure 3D), suggesting that UPF1 harbors two distinct
Regnase-1-interaction regions in the N-terminus and the
central parts. Regnase-1 interacted with CT UPF1 more
robustly than WT and NCT UPF1 (Figure 3D), sug-
gesting that the C-terminal region of UPF1 functions as
inhibitory domain for association with Regnase-1. Note-
worthy, we have previously shown that the interaction be-
tween Regnase-1 and UPF1 was not affected by the treat-
ment of cell lysates with an RNase Benzonase, indicating
that Regnase-1 and UPF1 directly interact at the protein
levels (21). Further co-immunoprecipitation assays iden-
tified that the RecA domain (610–914) in the central re-
gion of UPF1 was responsible for the association with a
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Figure 2. The unwinding of stem–loop by RNA helicase UPF1 induces RNA cleavage by Regnase-1. (A) AFM images of complex of DNA frame with
Il6 RNA and UPF1. (B and C) Time-lapse AFM images of complex of DNA frame with indicated Il6 stem–loop RNA, Regnase-1 and UPF1. Time 0
s is an arbitrary time during the AFM scanning. Scanning rate is 0.2 frames/s. (D) Regnase-1 cleaved the stem–loop RNAs in the presence of UPF1 in
vitro. Indicated 5′-32P-labeled RNAs were incubated with Regnase-1 and HA-UPF1 for indicated time, and analyzed by TBE–urea gel electrophoresis. (E)
Flow chart depicting experiments where 5′-32P-labeled Il6 stem–loop RNA was incubated with UPF1 at 37◦C for 10 min, purified at 4◦C and analyzed by
native PAGE electrophoresis. To keep unwinding structure of stem–loop RNA by UPF1, RNA was immediately incubated and kept at 4◦C after UPF1
treatment, and then incubated with Regnase-1. (F) Native PAGE analysis of Il6 stem–loop RNA treated with UPF1. (G) Regnase-1 cleaved the Il6 stem–
loop RNA treated with UPF1 in vitro. The Il6 stem–loop RNA treated with UPF1 were incubated with Regnase-1 for indicated time and analyzed by
TBE–urea gel electrophoresis. (H) Schematic illustration showing that the unwinding of stem–loop by UPF1 induces RNA cleavage by Regnase-1. See also
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Figure 3. Regnase-1 promotes ATPase/helicase activity of UPF1 by inhibiting interaction between UPF1 RecA and CH domain. (A) ATPase assay of
HA-UPF1 protein in the presence of Regnase-1. (B) Native PAGE analysis of Il6 stem–loop RNA. The 5′-32P-labeled RNAwas incubated with UPF1 and
Regnase-1, purified at 4◦Cand then analyzed by native polyacrylamide gel electrophoresis. (C) Schematic representation of humanUPF1.NCR,N-terminal
conserved region; CH, cysteine/histidine-rich domain; RecA, RecA-like domain; SQ, serine/glutamine motif. (D) Western blot analysis of HA-UPF1 and
indicated UPF1 mutants co-immunoprecipitated with Flag-Regnase-1 transiently-expressed in HeLa cells. (E) Immunoblot analysis of SBP-GFP-UPF1
and its deletion mutants co-immunoprecipitated with Flag-Regnase-1 transiently-expressed in HeLa cells. (F) Schematic representation of mouse Regnase-
1. (G)Western blot analysis of indicatedRegnase-1-mCherry deletionmutants co-immunoprecipitated withGFP-UPF1-(610–914) orGFP-UPF1-(6–429)-
T28E transiently-expressed in HeLa cells. (H) Immunoblot analysis of HA-UPF1-(6–429) and Flag-Regnase-1 co-immunoprecipitated with GFP-UPF1-
(610–914) transiently-expressed in HeLa cells. (I) Schematic illustration showing that Regnase-1 promotes ATPase/helicase activity of UPF1 by inhibiting






/nar/advance-article-abstract/doi/10.1093/nar/gkz628/5536979 by Kyoto D
aigaku N
ogaku-bu Toshoshitsu user on 23 July 2019
Nucleic Acids Research, 2019 11
ure 3E–G). Interestingly, the intramolecular interaction be-
tween the N-terminal half of UPF1 harboring the CH do-
main (6–429) and RecA domain (610–914) was inhibited
by the co-expression of Regnase-1 (Figure 3H). This find-
ing suggests that the binding of Regnase-1 to UPF1 RecA
domain inhibits the intramolecular interaction between the
RecA and CH domains of UPF1, allowing the activation of
theUPF1ATPase/helicase activity to trigger RMD (Figure
3I).
UPF1 T28 phosphorylation stabilizes interaction between
UPF1 and Regnase-1
In addition to the RecA domain, the N-terminal region of
UPF1 is essential for binding with Regnase-1. In NMD,
UPF1 N- and C-terminal regions (T28, S1078, S1096 and
S1116) are phosphorylated and bind with SMG6 and
SMG5-7, respectively (7,28,29,40). Interestingly, a single
point mutation of T28 to alanine (T28A), but not to glu-
tamate (T28E) or mutations at the C-terminal phosphory-
lation sites (4SA), abrogated the association of Regnase-
1 with UPF1 (Figure 4A and B and Supplementary Fig-
ure S1H). Indeed, treatment of cell lysates with  protein
phosphatase reduced the association between Regnase-1
and UPF1 (Supplementary Figure S1I). Reciprocally, a hy-
perphosphorylated UPF1 variant (G495R/G497E) (Sup-
plementary Figure S2A) (41,42) showed increased associ-
ation with Regnase-1 (Supplementary Figure S2B). To ex-
amine direct Regnase-1-UPF1 interaction in vitro, we per-
formed GST pull-down assay with Regnase-1 and UPF1-
T28E mutant and found that Regnase-1 directly associ-
ated with UPF1-T28E (Figure 4C). These results indicate
that UPF1 T28 phosphorylation is critical for stable as-
sociation with Regnase-1. Consistently, reconstitution of
UPF1 knockdown HeLa cells with WT and 4SA, but not
T28A, UPF1 rescued Regnase-1-mediated suppression of
a luciferase reporter harboring Il6 3′ UTR (17,21) (Fig-
ure 4D and E). Similarly, suppression of IL-1-mediated
expression of IL6 and PTGS2 required T28, but not 4S,
phosphorylation of UPF1 (Figure 4F). In contrast, both
T28A and 4SAUPF1mutants failed to suppress NMD tar-
get genes such as SMG5 and GAS5 (Supplementary Figure
S2C). Collectively, these results demonstrate that T28, but
not C-terminal, phosphorylation of UPF1 is essential for
RMD.
We next asked how Regnase-1 recognizes the phospho-
rylated UPF1 N-terminus. We found that the RNase do-
main (130–300) of Regnase-1 interacted with the T28-
phosphorylated (negatively charged) N-terminal half (6–
429) of UPF1 (Figure 4G and H). By constructing a struc-
tural model of the Regnase-1 RNase domain (134–296), we
identified four regions (regions 1–4) on the surface of the
Regnase-1 RNase domain that could potentially recognize
the phospho moiety via electrostatic interactions (Supple-
mentary Figure S2D and E). Among these, mutations of re-
gion 4 (K257A/R258A; KRAA), but not regions 1–3, abro-
gated the interaction with WT and phosphomimetic T28E
UPF1 (Figure 4I and Supplementary Figure S2F). Indeed,
a structural model of phosphothreonine (P-Thr) docked to
Regnase-1 RNase domain showed that K257R258 and glu-
tamine 254 (Q254) form a positively charged P-Thr binding
pocket (Figure 4J). Although K257 and R258 in Regnase-
1 are dispensable for its RNase activity in vitro (43), a
Regnase-1-KRAA mutant failed to suppress Il6 and Ptgs2
3′ UTRs (Figure 4K). These results suggest that Regnase-1
requires N-terminal UPF1 phosphorylation to form a sta-
ble association with UPF1, which, in turn, increases its he-
licase activity.
Regnase-1 induces T28 phosphorylation of UPF1 after asso-
ciation with the RecA domain
The results above indicate that UPF1 and Regnase-1 in-
teract in two distinct modes: UPF1 RecA with Regnase-
1 linker regions, and UPF1 P-T28 with Regnase-1 RNase
domain via K257/R258. Given that both interactions are
required for RMD in cells, we investigated their hierarchy
by focusing on the T28 phosphorylation of UPF1. First,
we discovered that the UPF1 T28 phosphorylation was in-
duced in macrophages stimulated with LPS (Figure 4L).
This stimulus upregulates the expression of Regnase-1 tar-
get mRNAs such as IL6 and NFKBIZ. We previously re-
ported that Regnase-1 protein is phosphorylated and re-
expressed in macrophages in response to LPS stimulation
(17,19). Regnase-1 phosphorylationwas detected as themo-
bility shift of the Regnase-1 bands (Figure 4L). Interest-
ingly, overexpression of Regnase-1 target mRNA also aug-
mented P-T28-UPF1, whereas C-terminal phosphorylation
ofUPF1was unchanged (Supplementary Figure S2G). Sur-
prisingly, UPF1 T28 phosphorylation was not induced in
Regnase-1-deficient macrophages (Figure 4L), indicating
that Regnase-1 is required for the phosphorylation ofUPF1
T28 upon inflammatory stimuli.
We next investigated how Regnase-1 induces UPF1
T28 phosphorylation by using HEK293T cells in which
Regnase-1 is rarely expressed. In this cell line, the expres-
sion of mRNAs harboring Il6 3′ UTR together with WT
Regnase-1 induced UPF1 T28 phosphorylation (Supple-
mentary Figure S2H).Whereas themutation ofK257/R258
in the Regnase-1 RNase domain (KKAA) did not affect in-
duced phosphorylation ofUPF1, lack of the linker (90–130)
region of Regnase-1 abrogated the phosphorylation. These
results suggest that the (90–130) region of Regnase-1 ini-
tially associates with the UPF1 RecA helicase domain dur-
ing translation, which allows phosphorylation of UPF1 at
T28, which is subsequently recognized by the RNase do-
main of Regnase-1 to mediate stable interaction between
UPF1 and Regnase-1.
SMG1 regulates RMD through phosphorylation of UPF1
UPF1 is a shared substrate of phosphatidylinositol 3-kinase
(PI3K)-related protein kinases (PIKKs), including SMG1,
ataxia-telangiectasia mutated (ATM), ATM- and Rad3-
related (ATR) andDNA-dependent protein kinase catalytic
subunit (DNA-PKcs) kinases (44). Therefore, we explored
kinase(s) essential for RMD through phosphorylation of
UPF1 by treatment with their specific inhibitors. Interest-
ingly, inhibition of SMG1, but not ATM, ATR or DNA-
PKcs, abrogated Regnase-1-mediated suppression of a lu-
ciferase reporter harboring Il6 and Ptgs2 3′ UTR (Fig-
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Figure 4. Phosphorylation of UPF1 at T28 is required for RMD. (A and B) Western blot analysis of HA-UPF1 and indicated UPF1 mutants co-
immunoprecipitated with Flag-Regnase-1 transiently-expressed in HeLa cells. (C) Western blot of GST pull-down assay showing the direct association
of Regnase-1 with UPF1. (D) Immunoblot analysis of UPF1 in HeLa cells transfected with siRNA specific for UPF1 and reconstituted with siRNA-
resistant HA-UPF1R-WT or indicated its mutants. (E) Luciferase activity of HeLa cells transfected with siRNA specific for UPF1 and reconstituted with
siRNA-resistantWTUPF1 or indicated its mutants and then transfected with indicated luciferase reporter plasmids, together with control plasmid (Mock)
or Regnase-1 expression plasmids. (F) RNA expression levels in HeLa cells transfected with siRNA specific for UPF1, reconstituted with siRNA-resistant
WT UPF1 or indicated its mutants. The cells were stimulated with IL-1 (10 ng/ml). (G and H) Western blot analysis of indicated Regnase-1-mCherry
deletion mutants co-immunoprecipitated with GFP-UPF1-(610–914) or GFP-UPF1-(6–429)-T28E transiently-expressed in HeLa cells. (I) Immunoblot
analysis of HA-UPF1 co-immunoprecipitated with Flag-Regnase-1 and its K257A/R258A (KRAA) mutant transiently-expressed in HeLa cells. (J) Struc-
tural model of phosphothreonine (P-Thr) docked to homology model of mouse Regnase-1 RNase domain (134–296). (K) Luciferase activity of HeLa
transfected with indicated luciferase reporter plasmids, together with control plasmid (Mock) or indicated expression plasmids. Unless otherwise indi-
cated, data are mean ± SD (n = 3). (L) Immunoblot analysis of P-T28-UPF1 and P-S1078/S1096-UPF1 in peritoneal macrophages from Regnase-1+/+
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Figure 5. SMG1 regulates RMD through the direct phosphorylation of UPF1. (A) Luciferase activity of HeLa cells treated with indicated inhibitors,
including Compound 11J (SMG1 inhibitor, 0.3M), KU-60019 (ATM inhibitor, 1M), VE-821 (ATR inhibitor, 1M) andNU7441 (DNA-PK inhibitor,
1 M), and transfected with indicated luciferase reporter plasmids, together with control plasmid or indicated expression plasmids. (B) HEK293 Tet-off
cells were transfected with siRNA specific for SMG1 and cotransfected with pTREtight-Il6 CDS-3′ UTR together with the Regnase-1 expression plasmid
or control (Mock) plasmid. Total RNAswere prepared after Dox (1g/ml) treatment, and Il6 and β-ActinmRNA levels were determined byNorthern blot
analysis. (C) Quantification of the autoradiographs in (B), presented as the ratio of Il6 to β-Actin (n = 3). (D) Luciferase activity of HeLa cells transfected
with indicated siRNA and luciferase reporter plasmids, together with control plasmid (Mock) or Regnase-1 expression plasmids. (E) RNA expression
levels in HeLa cells transfected with indicated siRNA and stimulated with IL-1 (10 ng/ml). (F) Western blot analysis of SMG1 in HeLa cells transfected
with siRNA specific for SMG1 and reconstituted with siRNA-resistant Flag-SMG R-WT or Flag-SMG1R-D2331A (DA), which is a kinase dead mutant.
(G) Luciferase activity of HeLa cells transfected with siRNA specific for SMG1 and reconstituted with siRNA-resistant WT or DA mutant of SMG1 and
then transfected with indicated luciferase reporter plasmids, together with control plasmid (Mock) or Regnase-1 expression plasmids. (H) RNA expression
levels in HeLa cells transfected with siRNA specific for SMG1, reconstituted with siRNA-resistant WT or DA mutant of SMG1 and then stimulated with
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tial for Regnase-1 function. Furthermore, knockdown of
SMG1 in HeLa cells inhibited T28-UPF1 phosphorylation
and the association between Regnase-1 and UPF1 (Sup-
plementary Figure S3A and B). When we knocked down
SMG1 in HEK293 Tet-off cells, overexpression of Regnase-
1 failed to destabilize Il6 mRNA (Figure 5B and C). Fur-
thermore, Regnase-1 overexpression no longer suppressed
the luciferase reporter harboring Il6 and Ptgs2 3′ UTRs
in SMG1 knockdown cells (Figure 5D). Moreover, knock-
down of SMG1 or Regnase-1 in HeLa cells resulted in in-
creased expression of endogenous IL6 and PTGS2, but not
NFKBIA, in response to IL-1 stimulation (Figure 5E).No-
tably, knockdown of both Regnase-1 and SMG1 did not
lead to additional increase in gene expression, suggesting
that Regnase-1 and SMG1 suppress gene expression via the
same pathway. Knockdown of Regnase-1, but not SMG1,
had no effect of expression of classical NMD substrates,
GAS5 and SMG5, suggesting that Regnase-1 has no effect
on NMD (Supplementary Figure S3C). Reconstitution of
SMG1 knockdown cells with WT, but not kinase inactive
mutant (D2331A, DA) SMG1 (28,45), rescued Regnase-1-
mediated suppression of Il6 and Ptgs2 3′ UTRs (Figure 5F
and G) as well as inhibition of IL6 and PTGS2 in IL-1-
stimulatedHeLa cells (Figure 5H). Reconstitution withWT
SMG1, but not DAmutant, rescuedNMD (Supplementary
Figure S3D). These results indicate that SMG1 is an essen-
tial kinase for the regulation of RMD through phosphory-
lation of UPF1.
Regnase-1 suppresses inflammatory mRNAs following a pio-
neer round of translation
We next sought to identify the biological significance of
the unique translation-dependent RMD molecular switch.
We first focused on the character of mRNAs degraded
by Regnase-1 during translation. Newly synthesized mR-
NAs bound by the nuclear cap-binding protein complex
CBP80/20 (CBC) undergo a pioneer round of translation,
and CBC-bound mRNPs are remodeled to the cytoplas-
mic cap-binding protein eIF4E for steady state transla-
tion (46,47). NMD targets CBP80-bound mRNAs in ad-
dition to eIF4E-associated mRNAs (48,49). Interestingly,
co-immunoprecipitation experiments revealed that catalyt-
ically active Regnase-1 bound to CBP80-associated, but
not to eIF4E-bound, mRNAs in HeLa cells (Supplemen-
tary Figure S3E). In contrast, Regnase-1-DN mutant co-
precipitated with both CBP80 and eIF4E, suggesting that
Regnase-1 degrades target mRNAs before they can be
bound by eIF4EmRNAs. This interaction was lost by treat-
ment with Benzonase before immunoprecipitation, indicat-
ing that they are RNA-mediated interactions, but not direct
protein-protein interactions.
We then investigated whether Regnase-1 has the poten-
tial to destabilize mRNAs at the pioneer round of trans-
lation. We performed an RIP assay with CBP80 or eIF4E
antibodies in Regnase-1-deficient (Regnase-1–/–; KO) HeLa
cells (Supplementary Figure S3F and G). Regnase-1 defi-
ciency caused the increase of CBP80-bound mRNAs, in-
cluding the target IL6, PTGS2 and NFKBIZ, but not
the non-target NFKBIA. Regnase-1 targets also increased
in eIF4E-associated mRNAs in Regnase-1–/– cells, since
CBP80 is replaced with eIF4E. To examine the impact of
Regnase-1 on CBP80-bound mRNAs comprehensively, we
performed RNA-immunoprecipitation sequencing (RIP-
seq) for CBP80- or eIF4E-associated mRNAs in Regnase-
1–/–HeLa cells. Regnase-1-targetedmRNAs, including IL6,
PTGS2, NFKBIZ and NFKBID, were enriched, even in
CBP80-boundmRNAs fromRegnase-1–/– HeLa cells, com-
pared with control (Figure 6A). Most genes were plotted
on the diagonal line in the scatter plot of fold-changes
between Regnase-1-WT and -KO in CBP80-RIP against
eIF4E-RIP and the difference betweenRegnase-1-WT and -
KO in the eIF4E-RIP was almost the same as in the CBP80-
RIP (SupplementaryFigure S3H), suggesting thatRegnase-
1 regulates CBP80-mRNAs. We have previously identified
68 Regnase-1-associated mRNAs by RIP-seq analysis (21).
Gene set enrichment analysis (GSEA) revealed that the 68
Regnase-1-interacting mRNAs were significantly enriched
in the CBP80-bound mRNAs in Regnase-1–/– cells with
high enrichment scores (ES) (Max. ES = 0.295, P < 10−8;
Figure 6B). These results are consistent with a scenario in
which Regnase-1 deficiency upregulates target mRNAs at
the pioneer round of translation.
We next explored whether the regulation of mRNAs
in the pioneer round of translation is common to RNA-
binding proteins controlling immune responses. We have
reported that Regnase-1 and Roquin recognize common
stem–loop structures (21), though Roquin-mediated degra-
dation of inflammatorymRNAs is not dependent onUPF1.
In contrast to Regnase-1, both overexpressed and endoge-
nous Roquin bound eIF4E-associated, but not CBP80-
associated, mRNAs (Figure 6C and Supplementary Figure
S3E). Consistently, theRoquin-1San/San mouse embryonic fi-
broblast (MEFs), harboring a M199R hypomorphic muta-
tion in Roquin-1 alleles (50,51), showed increased expres-
sion of eIF4E-bound, but not CBP80-bound, target mR-
NAs compared with WT cells upon LPS stimulation (Fig-
ure 6Dand SupplementaryFigure S4A).On the other hand,
Regnase-1–/– MEFs exhibited even an increase in CBP80-
bound mRNAs. Moreover, Regnase-1 deficiency increased
the mRNA half-lives (t1/2) of CBP80- as well as eIF4E-
bound mRNAs encoding Ptgs2 and Nfkbiz in MEFs, al-
though Roquin-1San/San MEFs showed the increased t1/2 of
eIF4E-boundmRNAs (SupplementaryFigure S4B).Recip-
rocally, overexpressed Regnase-1 decreased both CBP80-
and eIF4E-bound mRNAs encoding PTGS2 and NFK-
BIZ in HeLa cells upon IL-1 stimulation; whereas, over-
expression of Roquin destabilized eIF4E-bound mRNAs
alone (Figure 6E and Supplementary Figure S5A). Fur-
thermore, overexpression of Regnase-1 reduced the t1/2 of
CBP80- as well as eIF4E-bound mRNAs, although overex-
pression of Roquin decreased the t1/2 of eIF4E-bound mR-
NAs alone (Supplementary Figure S5B). Notably, knock-
down of SMG1 also increased CBP80- as well as eIF4E-
bound Regnase-1-target mRNAs (Supplementary Figure
S5C). Taken together, the SMG1-Regnase-1 pathway po-
tently destabilizes mRNAs undergoing pioneer rounds of
translation, whereas Roquin regulates mRNAs that have
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Figure 6. Regnase-1 binds and suppresses inflammatory mRNAs undergoing pioneer rounds of translation. (A) Scatter plot of expression changes of
CBP80- and eIF4E-associated mRNAs upon IL-1 stimulation (10 ng/ml, 2 h) in Regnase-1-KO HeLa cells. CBP80- and eIF4E-associated mRNAs were
immunoprecipitated and analyzed bymRNA-sequence in biological duplicate. Regnase-1 target mRNAs defined fromRegnase-1 RIP-Seq (P< 0.001) were
indicated. (B) GSEA of overlap between 68 genes enriched in Regnase-1 RIP-seq (P < 0.001) and genes sorted by CBP80 or eIF4E RIP-seq enrichments
in Regnase-1-KO cells. The ES plots were shown with genes ranked according to their CBP80 or eIF4E RIP-seq enrichments P value. (C) Western blot
analysis of Flag-Regnase-1 and Flag-Roquin-1 co-immunoprecipitated with CBP80 or eIF4E in HeLa cells. (D) RNA expression levels of CBP80- and
eIF4E-associated mRNAs in MEFs stimulated with LPS (100 ng/ml) for 2 h. (E) RNA expression levels of CBP80- and eIF4E-associated mRNAs in
HeLa cells transfected with Flag-Regnase-1 or Flag-Roquin expression plasmid and stimulated with IL-1 (10 ng/ml) for 2 h. (F) The protein/mRNA
ratio of PTGS2 and NFKBIZ in HeLa cells transfected with the control (Mock), Flag-Reg1 or Flag-Roquin expression plasmid and stimulated with IL-1
(10 ng/ml). RNA and protein expression profiles of PTGS2 and NFKBIZ are shown in Figures S6A and S6B. The data were normalized to maximum
values. (G) Diagram of transcription-translation process mediated by Regnase-1 (Reg1) and Roquin. CBP80-bound mRNA and eIF4E-bound mRNA
were described as CBP80-mRNA and eIF4E-mRNA, respectively. Dashed arrow indicates stimulus-induced activation. Solid arrow indicates reactions
of transcription, translation and degradation. (H) Fitting of the mathematical models to the experimental data. Circles indicate experimental values of
PTGS2 mRNA and protein in each condition. Green lines indicate simulation results in different numerical conditions where stoichiometric ratios of
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Modeling inflammatory gene expression from pioneer and
steady state rounds of translation
We next addressed the question of how RMD following pi-
oneer rounds of translation contribute to the regulation of
inflammation. By experimental analysis on the effects of
Regnase-1 and Roquin in the expression of target mRNAs
and proteins, we found that Regnase-1 is potent to suppress
the protein/mRNA ratio compared to control cells (Fig-
ure 6F and Supplementary Figure S6A and B). In contrast,
Roquin expression affected mRNA and protein expression
to a similar extent, though both Regnase-1 and Roquin-
based degradation exhibit similar kinetics.
These experimental findings prompted us to decipher
the dynamics of post-transcriptional regulation systems of
inflammation by Regnase-1 and Roquin using a mathe-
matical model. Our model includes, along with the trans-
lated proteins, two states for the mRNAs: those undergo-
ing a pioneer round (CBP80-bound) and those undergoing
steady state rounds (eIF4E-bound) of translation (Figure
6G). Based on the experimental results, we assumed that
Regnase-1 induces degradation of both the CBP80- and
eIF4E-bound fractions of mRNAs, and Roquin only de-
grades the eIF4E-bound mRNA fraction. Because eIF4E-
mRNAs mediate steady-state translation and it is consid-
ered that steady-state translation synthesizes much pro-
tein in polysome state, we assumed that the input-output
relationship between mRNA and protein is nonlinear in
eIF4E-mRNAs. On the other hand, CBP80-mRNAs medi-
ate pioneer round of translation and it is considered that
pioneer round of translation produces less protein than
steady-state translation. Thus, we hypothesize that the re-
lationship between mRNA and protein is linear in CBP80-
mRNAs. Indeed, we confirmed, by fitting an assumed equa-
tion (Figure 6H, green line), that the input-output rela-
tionship between mRNA and protein in the experiment is
nonlinear in eIF4E-bound mRNAs, probably representing
that steady-state translation synthesizes much protein in
polysome state. This effect was incorporated into the model
by representing eIF4E-bound (E) mRNA translation by a
Hill equation, while CBP80-bound mRNA translation was
represented as a linearmodel (Figure 6H,Method). Simula-
tion using themodel qualitatively recapitulated dynamics of
protein/mRNA in PTGS2 and NFKBIZ (Supplementary
Figure S6C and S6D, for experimental data 6F, S5A, S6A,
Supplementary Tables S1 and S2), indicating that themodel
essentially explains the time-course kinetics of the transla-
tion process and therefore can generate predictions of un-
derlying mechanisms. To compare influences of Regnase-1
and Roquin on the dynamics of the synthesized protein, we
checked the translation rates of protein from CBP80- and
eIF4E-bound mRNA in the simulation results. Interest-
ingly, the translation rate of eIF4E-bound mRNA in Flag-
Regnase-1-overexpressed cells was significantly lower than
in the WT and Flag-Roquin expressing cells (Supplemen-
tary Figure S6E, circles). Given that Regnase-1 suppresses
CBP80-bound mRNA, which further affects eIF4E-bound
mRNA, the amount of eIF4E-mRNA in Flag-Regnase-1
cells was not beyond a threshold (km) value; therefore, it
could not efficiently translate proteins (Supplementary Fig-
ure S6E, red circle, Supplementary Figure S6F). On the
other hand, translation rates of CBP80-mRNA were com-
parable in Regnase-1- and Roquin-expressing cells. To in-
vestigate the reason why the difference in the translation
rates of eIF4E-bound mRNA occurred, we performed sen-
sitivity analysis which examines how perturbations to the
Regnase-1- (k4, k6) and Roquin-induced degradation (k7)
in the model affect the eIF4E-mRNA. This analysis showed
that Regnase-1-induced degradation (k4) in PTGS2 and
NFKBIZ yield the greatest change in eIF4E-mRNA, even if
Roquin is overexpressed (Supplementary Figure S6G) and
the effect is transmitted to the protein level (Supplemen-
tary Figure S6H). Taken together, our mathematical model
reveals that the effects of Regnase-1 and Roquin can best
be recapitulated by considering pioneer and steady state
rounds of translation separately.
Control of DCmaturation and proinflammatory gene expres-
sion by SMG1 inhibition
The requirement of SMG1 in RMD prompted us to ex-
amine the possibility of immune responses being manipu-
lated by controlling SMG1 activity. When we treated bone
marrow–derivedDCs (BMDCs) with a SMG1 inhibitor (re-
ferred to as ‘Compound 11J’ in (27)) (Figure 7A), the phos-
phorylation of UPF1 at T28 was profoundly suppressed
in unstimulated or Pam3CSK4 (TLR2 ligand)-treated cells
(Figure 7B). Treatment with the SMG1 inhibitor in WT
BMDCs resulted in increased expression of Il6 and Ptgs2,
but not Tnf and Nfkbia, in response to Pam3CSK4 stim-
ulation (Figure 7C). Lack of Regnase-1 increased inflam-
matory gene expression (Supplementary Figure S7A and
S7B) and the SMG1 inhibitor had no effect on their expres-
sion in Regnase-1–/–BMDCs (Supplementary Figure S7C),
indicating that SMG1 regulates cytokine expression in a
Regnase-1-dependent manner. In addition to proinflam-
matory cytokines, the expression levels of co-stimulatory
molecules, Cd40 and Cd80, was enhanced by the treat-
ment with the SMG1 inhibitor in BMDCs (Figure 7C).
Production of IL-6, but not TNF, was increased by treat-
ment with the SMG1 inhibitor in response to all TLR
ligands, Pam3CSK4 (TLR2), LPS (TLR4), R848 (TLR7)
and CpG-DNA (TLR9), in BMDCs (Figure 7D), indicat-
ing that SMG1 regulates cytokine expression at the post-
transcriptional level through the Regnase-1 pathway in in-
nate immune cells.
Next, we investigated the effect of SMG1 inhibition on
the maturation of DCs. Treatment with the SMG1 in-
hibitor augmented the surface expression of CD40 and
CD80 with or without stimulation with a TLR2 ligand
(Figure 7E). As expected, expression levels of CD40 and
CD80 increased in Regnase-1–/– BMDCs (Figure S7D) and
Cd40 and Cd80 mRNA expressions were also upregulated
in Regnase-1–/– BMDCs compared with wild-type controls
(Supplementary Figure S7B). Moreover, Regnase-1 overex-
pression suppressed the luciferase reporter construct har-
boring Cd40 and Cd80 3′ UTRs in an RNase activity-
dependent manner (Figure 7F). Consistent with augmented
expression of co-stimulatory molecules, allogeneic mixed
lymphocyte reaction (MLR) assays of splenic CD4+ T cells
with BMDCs revealed that treatment with a SMG1 in-
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Figure 7. Control of DCmaturation by manipulating SMG1 activity. (A) Chemical structure of SMG1 inhibitor. (B) Immunoblot analysis of P-T28-UPF1
and P-S1078/S1096-UPF1 in BMDCs cultured with Pam3CSk4 (1 ng/ml) and/or SMG1 inhibitor (0.3 M) for 2 h. (C) RNA expression levels in BMDCs.
The BMDCs from C57BL/6J mice were treated with SMG1 inhibitor (0.3 M) and stimulated with Pam3CSK4 (1 ng/ml). (D) BMDCs from C57BL/6J
mice were treated with SMG1 inhibitor (0.3 M) and stimulated with Pam3CSK4 (10 ng/ml), LPS (100 ng/ml), R848 (100 nM) or CpGDNA (ODN1668,
100 nM) for 24 h. Production of IL-6 and TNF in the culture supernatant were measured by ELISA. (E) Expression levels of CD40 and CD80 on BMDCs.
The BMDCs from C57BL/6J mice were cultured with Pam3CSK4 (1 ng/ml) and/or inhibitor (0.3 MSMG1) for 48 h and expression of CD40 and CD80
on BMDCs were analyzed by Flow cytometry. (F) Luciferase activity of HEK293T cells transfected with indicated luciferase reporter plasmids, together
with control plasmid (Mock) or Regnase-1 expression plasmids. (G) Allogeneic mixed lymphocyte reaction of splenic CD4+ T cells from C57BL/6J mice
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tivity, which was further enhanced by co-stimulation with
Pam3CSK4 (Figure 7G). Collectivity, these data demon-
strate that DC maturation can be precisely manipulated by
controlling SMG1 kinase activity by using an inhibitor via
Regnase-1-mediated inflammatory mRNA degradation.
DISCUSSION
In this study, multiple lines of evidence suggest that trans-
lation termination induces unwinding of Regnase-1 target
stem–loop RNAs by UPF1, after which RMD proceeds
(Figure 8). Previously described mechanisms of gene reg-
ulation by mRNA involve recruitment of RNases to target
mRNAs, or dimerization of the RNases to activate RNase
activity. To our knowledge, structural changes in the tar-
get RNA itself that act as a molecular switch to activate
RNA degradation have not been reported. The interaction
between Regnase-1 with UPF1 described here explains the
role of the stem–loop structure in both recruiting Regnase-
1 and in regulating mRNA degradation during a pioneer
round of translation.
Recent studies imply that endoribonucleases often collab-
orate with RNA helicases. This is exemplified by the rela-
tionship between SMG6 and UPF1 in NMD. The mech-
anism triggering RMD is reminiscent of NMD, in which
UPF1 ATPase/helicase activity is essential. However, there
is a clear difference between NMD and RMD. It was re-
ported that UPF1 is required for the recruitment of SMG6
to NMD-targeted mRNAs by protein-protein interactions.
Although UPF1 ATPase activity is required for mRNP dis-
assembly and target discrimination in the NMD system, the
requirement of UPF1 ATPase/helicase activity for NMD
mRNA cleavage is obscure (24,25). On the other hand,
UPF1 helicase-based remodeling RNA structure is directly
required for initiation of RMD. Therefore, RMD possesses
a heretofore undescribed mechanism by which RNA struc-
tural changes induced by UPF1 serve as a switch to activate
Regnase-1.
A related example is an endoribonuclease Zucchini and
an RNA helicase Armitage in the generation of piR-
NAs (52,53). Both Zucchini and Armitage are essen-
tial for piRNA biogenesis, but the molecular mechanism
of Armitage- and Zucchini-mediated endoribonucleolytic
cleavage has yet to be clarified. We speculate that RNA
structural changes that act as a molecular switch for RNA
cleavage are utilized by various endoribonucleases, includ-
ing Zuccini-Armitage axis.
It is also known that RNA secondary structures can serve
as the barrier for RNA degradation by non-specific exori-
bonucleases, and that RNA helicases in close association
with non-specific RNases (for example, PNPase and RNase
E) enhance the degradation of structured RNA (54). On
the other hand, previously described sequence-specific or
sequence-limited RNases (for example, RNase III family,
RNase H, RNase A or RNase T1) do not require RNA
structural changes to induce specific RNA cleavage (55).
Thus, RNases might have developed multiple mechanisms
to regulate degradation of target RNAs.
Considering the potentially deleterious effects of cy-
tokine protein expression, the UPF1-mediated RNA struc-
tural change very likely functions as an essential timer for
mRNA degradation by Regnase-1. This timing is achieved
by the synergistic interaction between Regnase-1 andUPF1
following the pioneer round of translation, which, in turn,
enhances the helicase activity of UPF1. We found that
both the N-terminal region and RecA helicase domain of
UPF1 are responsible for interaction between Regnase-1
and UPF1, whereas the C-terminal region of UPF1 func-
tions as inhibitory domain for association with Regnase-
1, suggesting that there is possibility that the C-terminal
region of UPF1 inhibits the binding of Regnase-1 to the
UPF1 N-terminal or central region. Future studies will re-
veal how the C-terminal region of UPF1 regulates RMD.
Additionally, we found that the association between the dis-
ordered linker region of Regnase-1 and UPF1 RecA he-
licase domain is responsible for inducing UPF1 helicase
activity by inhibiting intramolecular interactions with the
CH domain. In NMD, it was reported that UPF2 asso-
ciates with the CH-domain of UPF1 following the termina-
tion of translation (39,56), and subsequent conformational
changes in UPF1 enhance the ATPase activity (39). On the
other hand, Regnase-1 interacts with the RecA domain, but
not the CH domain, of UPF1 via the Regnase-1-(90–130)
linker region and UPF2 is dispensable for RMD (21). Fu-
ture structural studies will uncover themechanism by which
Regnase-1 changes the conformation of UPF1, thus poten-
tiating helicase activity by inhibiting the intramolecular in-
teraction between the CH and RecA domains.
Consistent with these observations, we found that the
phosphorylation of UPF1 at T28 is critical for stable inter-
action between Regnase-1 and UPF1 in cells. On the other
hand, efficient degradation of target RNA by Regnase-
1 was observed in the absence UPF1 phosphorylation
or SMG1 in vitro system. Because high concentration of
Regnase-1, UPF1 and target mRNA can induce the asso-
ciations at high frequencies in vitro, RMD appears to be in-
duced in the absence of UPF1 phosphorylation or SMG1 in
vitro. In NMD, SMG6 is recruited to target mRNAs by the
recognition of phospho-T28 ofUPF1 via the 14-3-3-like do-
main (7). However, Regnase-1 does not harbor a 14-3-3-like
domain; rather, the positively charged region in the RNase
domain of Regnase-1 is responsible for the binding with the
T28-phosphorylated UPF1. The interaction between the
phospho-moiety and Regnase-1 RNase domain appears to
be stable. Given the fact that recognition of phospho-T28 in
UPF1 is essential for RMD, it is possible that the formation
of a stable complex is critical for the execution of degrada-
tion by combining theUPF1 helicase andRegnase-1 RNase
activities.
We identified SMG1 as a kinase that carries out UPF1
phosphorylation at the N-terminal end and is essential for
Regnase-1 activity. In addition to NMD, UPF1 has been
shown to be essential for translation-dependent mRNA
degradation pathways such as Staufen-mediated decay,
replication-dependent histone mRNA decay and mainte-
nance of telomere length via the regulation of long non-
coding telomeric repeat–containing RNA (TERRA) (46).
However, other than the reported hyper-phosphorylation of
UPF1 by ATR and DNA-dependent protein kinase in the
previously described replication-dependent histone mRNA
(57), it is not clear if UPF1 activity is generally regulated
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Figure 8. A proposed model of mRNA degradation by Regnase-1 and Roquin. Regnase-1 recognizes stem–loop on 3′ UTR of inflammatory mRNAs
prior to binding with UPF1 and translation. In the Regnase-1 pathway, SMG1 phosphorylates UPF1 at T28, which is supported by the association of
Regnase-1-(90-130) linker region with UPF1 RecA helicase domain. The T28-phosphorylated N-terminal region of UPF1 is associated with Regnase-1
RNase domain (K257R258) to form stable interaction between Regnase-1 and UPF1. The association with Regnase-1 promotes UPF1 ATPase/helicase
activity and the unwinding of stem–loop by UPF1 helicase activity induces RNA cleavage by Regnase-1. The SMG1-UPF1–Regnase-1 axis destabilizes
inflammatory mRNAs bound by CBP80 during pioneer round of translation, whereas Roquin regulates mRNAs bound by eIF4E after steady-state round
of translation. NCR, N-terminal conserved region; RecA, RecA-like domain.
be more similar to NMD than to other UPF1-dependent
RNA-degradation pathways.
Interestingly, T28-phosphorylation of UPF1 was rapidly
induced in innate immune cells in response to TLR stim-
ulation. One possible explanation for this is that an in-
crease in Regnase-1 target mRNAs by TLR stimulation
also induces the phosphorylation of UPF1. Alternatively,
SMG1 kinase activity itself might be directly regulated in
the course of the TLR signaling. Indeed, it is well known
that the PI-3 kinase, which is related to SMG1, is activated
in response to TLR ligands, and further activates down-
stream Akt/mTOR, thereby inhibiting TLR-induced in-
flammatory responses (58). SMG1 is reported to form a
complex with SMG8 and SMG9, which suppress SMG1
kinase activity to modulate NMD (59,60), suggesting that
SMG1 kinase activity can be regulated by modulating the
SMG1 complex. Future studies will reveal if there are sig-
naling pathways that directly control SMG1 phosphoryla-
tion of UPF1 in order to control immune cell activation.
In mice, SMG1 deficiency leads to embryonic lethal-
ity at day 8.5, due to impaired NMD (61). Nevertheless,
Smg1 gene-trap heterozygous (Smg1+/gt) mice showed in-
creased production of cytokines, including Il6, and devel-
oped chronic inflammation (62). Surprisingly, NMD was
not impaired in the Smg1+/gt mice irrespective of the se-
vere defect in SMG1 expression. The phenotype is consis-
tent with our finding that SMG1 regulates cytokine expres-
sion at the post-transcriptional level through the Regnase-1
pathway. Thus, the SMG1-UPF1–Regnase-1 pathway ap-
pears to be critical for cytokine expression in vivo.
We propose that Regnase-1 is essential for efficiently de-
grading inflammatory mRNAs undergoing pioneer rounds
of translation. Although extensive studies showed that var-
ious RNA binding proteins such as ARE-BPs and Roquin
recognize cis-elements present in the 3′ UTRs in inflamma-
torymRNAs in order to carry out degradation, to date none
have implicated the importance of mRNA translation sta-
tus. We found that RMD significantly restricts the number
of proteins produced by an mRNA, and that this can be
explained by our mathematical model in terms of regula-
tion at the pioneer round of translation. This mechanism
enables rapid degradation of inflammatory genes when the
transcriptional supply ceases through clearance of inflam-
matory stimuli such as pathogens. A recent intriguing study
shows that Regnase-1 functions to silence translation (63),
though the molecular mechanism of how Regnase-1 in-
hibits protein synthesis is unclear. Our model indicates that
Regnase-1 controls mRNAs undergoing initial rounds of
translation, resulting in the decrease of protein production
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plain the function of Regnase-1 on the inhibition of trans-
lation.
Inhibition of SMG1 by a low molecular weight com-
pound induced DC maturation by suppressing RMD. The
compound, 11J, has been characterized as a highly specific
SMG1 inhibitor that does not affect other PI-3 kinases (27).
However, it was not known that SMG1 inhibition potenti-
ates inflammation by suppressing RMD. Not only cytokine
mRNAs, but also co-stimulatory molecules such as CD40
and CD80 expression, are up-regulated by lack of Regnase-
1 or inhibition of SMG1. These co-stimulatory molecules
are also directly regulated by Regnase-1 via their 3′ UTRs.
Therefore, inhibition of SMG1 is an ideal way to potentiate
innate immune cell activation, and a SMG1 inhibitor could
be beneficial therapeutically.
In conclusion, this study provides a much clearer under-
standing of the synergistic relationship between Regnase-1,
UPF1 and the stem–loop structures of RMD-targeted mR-
NAs. RNA structural changes play a critical role in a switch
that controls their degradation. An understanding of post-
transcriptional regulation of inflammatory genes requires
consideration of pioneer rounds of translation as a critical
regulation phase that is separate from regulation of steady-
state translation. Specifically, the SMG1–UPF1–Regnase-
1 pathway targets inflammatory mRNAs efficiently utilizes
this phase. Reciprocally, manipulation of Regnase-1 activ-
ity via a SMG1 inhibitor is shown to potentiate innate
immune cell activation. Thus, therapeutic targeting of the
post-transcriptional regulation of inflammatory mRNAs
could be beneficial for the development novel vaccine ad-
juvants.
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